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CD38 is expressed in several types of non-Hodgkin lymphoma (NHL)and constitutes a promising target for antibody-based therapy.Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody
approved for the treatment of relapsed/refractory (R/R) multiple myeloma
(MM). It has also demonstrated clinical activity in Waldenström macroglob-
ulinaemia and amyloidosis. Here, we have evaluated the activity and mech-
anism of action of daratumumab in preclinical in vitro and in vivomodels of
mantle cell lymphoma (MCL), follicular lymphoma (FL) and diffuse large 
B-cell lymphoma (DLBCL), as monotherapy or in combination with stan-
dard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated
cytotoxicity by antibody-dependent cell cytotoxicity and antibody-depen-
dent cell phagocytosis in all lymphoma subtypes. In the presence of human
serum, complement-dependent cell cytotoxicity was marginally engaged.
We demonstrated by Selective Plane Illumination Microscopy that daratu-
mumab fully penetrated a three-dimensional (3D) lymphoma organoid and
decreased organoid volume. In vivo, daratumumab completely prevents
tumor outgrowth in models of MCL and FL, and shows comparable activity
to rituximab in a disseminated in vivo model of blastic MCL. Moreover,
daratumumab improves overall survival (OS) in a mouse model of trans-
formed CD20dim FL, where rituximab showed limited activity.
Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in
MCL and FL xenografts. Furthermore, in a patient-derived DLBCL
xenograft model, daratumumab anti-tumor activity was comparable to R-
CHOP and the addition of daratumumab to either CHOP or R-CHOP led
to full tumor regression. In summary, daratumumab constitutes a novel
therapeutic opportunity in certain scenarios and these results warrant fur-
ther clinical development.
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ABSTRACT
Introduction
B-cell non-Hodgkin’s lymphoma (B-NHL) constitutes 4-
5% of all hematologic neoplasia with increasing incidence
in western countries.1 DLBCL and FL represent the most fre-
quent aggressive and indolent NHL, accounting for approx-
imately 35% and 20% of all lymphomas, respectively.2,3
Moreover, roughly one third of FL patients develop a histo-
logic transformation (tFL) to DLBCL leading to a dismal
prognosis.4 Both entities are currently treated with chemo-
immunotherapy including a rituximab backbone.5,6 FL
responses are usually high, although recurrence occurs in
the majority of the cases.7 In DLBCL, currently classified
into germinal center type (GCB) or activated B-cell type
(ABC),8 treatment is not guided by subtype, and responses
to chemo-immunotherapy are normally higher in the GCB
subtype. Nevertheless, a portion of DLBCL (20%) do not
respond to this regimen.9 Several second-generation anti-
CD20 antibodies, such as the Food and Drug
Administration-approved obinutuzumab have been clini-
cally tested to overcome these limitations.10,11 However, an
alternative evolving therapeutic approach is to target a dif-
ferent antigen. In this regard, both FL and DLBCL originate
in the germinal center (GC) and consequently express high
levels of CD38, making this molecule an attractive thera-
peutic target.12
MCL is a rare NHL (6% of all NHL) with an aggressive
evolution and clinically challenging.13,14 Its frontline therapy,
although heterogeneous, typically consists of rituximab-
based chemo-immunotherapy followed by autologous-
stem cell transplantation and/or rituximab maintenance.
Even with intensive therapy, MCL patients ultimately
relapse.15 Novel targeted therapies currently approved for
R/R MCL include14 the mTOR inhibitor temsirolimus, the
immunomodulatory agent lenalidomide, the proteasome
inhibitor bortezomib,16 also approved in front-line, and the
BTK inhibitor ibrutinib that achieves the highest response
rates.17 However, MCL patients failing ibrutinib treatment
have very limited therapeutic options.18 In this situation,
where virtually all MCL cases express some level of CD38,
this antigen represents a potential alternative target to be
explored. Moreover, CD38 is associated with nodal disease
and poorer survival19,20 and high CD38 expression correlates
with poor in vivo response to bortezomib.21 Thus, targeting
CD38 could hold promise as a strategy for MCL, also in
bortezomib resistant tumors.
CD38 is present at high levels in bone marrow (BM) pre-
cursor cells and it is downregulated in resting normal B cells.
The molecule is re-expressed at high density once naïve B
lymphocytes are activated, and peaks when B cells enter
the GC. Terminally differentiated plasma cells and their
pathological counterparts express the highest surface densi-
ty among human cells, while it is completely absent in
memory B cells.22 CD38 behaves simultaneously as an
enzyme and as a receptor. The extracellular domain of
CD38 contains an enzymatic site that can generate cyclic
ADP ribose (cADPR) and ADPR from nicotine adenine din-
ucleotide (NAD+). This control of adenosine synthesis by
CD38 may be important in the context of the characteristic
immunosuppressive tumor microenvironment.
Daratumumab (Darzalex) is a first-in-class, human IgG1κ
monoclonal antibody (mAB) that targets the CD38 epitope.
It was approved by the Food and Drug Administration in
2015 as a monotherapy for patients with MM, who have
received at least three prior therapies.23 Currently, daratu-
mumab has been approved in combination with dexam-
ethasone plus either lenalidomide or bortezomib, or poma-
lidomide for the treatment of relapsed MM patients.24
Daratumumab has a broad-spectrum killing activity in MM
engaging complement-dependent cytotoxicity (CDC), anti-
body-dependent cellular cytotoxicity (ADCC),25 antibody-
dependent cellular phagocytosis (ADCP),26 and apoptosis.27
Moreover, daratumumab modulates the enzymatic activity
of CD3828 and induces an immunomodulatory role in MM
by depleting CD38+ immune suppressive cells29 contributing
to its antitumor activity. In chronic lymphocytic leukemia
(CLL), we have demonstrated that daratumumab induces
cytotoxic activity in vitro via ADCC and ADCP in primary
CLL cells and cell lines. In vivo, daratumumab significantly
prolongs OS of animals in systemic CLL murine models.
Daratumumab also affects tumor-microenvironment inter-
actions by blocking CLL homing and dissemination to sec-
ondary lymphoid organs in vitro and in vivo.30
In the present study, we aimed to investigate in vitro and
in vivo activity of daratumumab on MCL, FL and DLBCL




Daratumumab (Darzalex, anti-CD38mAb, IgG1) and the iso-
type control mAb (CNTO 3930, IgG1) were provided by Janssen.
Rituximab (Mabthera, anti-CD20 mAb, IgG1) and the chemother-
apy regimen CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisone) were obtained from the department of pharmacy
of the Hospital Clínic of Barcelona. 
Subcutaneous pre-emptive mouse models
SCID mice (Janvier Laboratories) were subcutaneously (sc)
injected with 10x106 RL-luc cells in the FL model or 10x106 REC-1
cells in the MCL model, respectively, following a protocol
approved by the Animal Testing Ethic committee of the University
of Barcelona and Generalitat de Catalunya (Protocol # 9971). Mice
were randomly assigned into cohorts of six mice per group and
received one intraperitoneal (ip) injection of 10 mg/kg of daratu-
mumab or isotype control every other week, starting the day of
cell inoculation.
Patient-derived DLBCL xenograft model
ST1361 is a DLBCL patient-derived xenograft model developed
using a DLBCL tumor originated in a metastatic site from a 
58-year-old chemotherapy-naïve Hispanic male.  ST1361 was
GCB subtype transformed from an Epstein-Barr virus negative FL
tumor.
The DLBCL tumor was homogeneously chopped into frag-
ments of similar size and injected sc into SCID mice. Treatment
was initiated when mean tumor volume was approximately 
150-250 mm3.  Daratumumab 20 mg/kg was administered weekly
for three weeks alone or in combination with CHOP (20 mg/kg
cyclophosphamide, 1.25 mg/kg doxorubicin, 0.2 mg/kg vincristine
[intravenously on Day 0], and 0.15 mg/kg prednisone [Days 0-4];
once a day (QD) for five days) or R-CHOP (10 mg/kg rituximab
[intraperitoneally on Day 0]+ CHOP as before). 
Statistical analysis
Unpaired and paired t-tests were used to assess statistical differ-
ences between two groups using GraphPad Prism software 4.0.
For Kaplan-Meier survival curves, SPSS19 software was used.
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Additional methodologic details are described in the Online
Supplementary Materials and Methods.
Results
Daratumumab induces cell killing in the presence of
external effectors in B-NHL
We first assessed by calcein-AM release assay, the abili-
ty of daratumumab to induce ADCC, ADCP and CDC in
MCL, FL and DLBCL cell lines. Using peripheral blood
mononuclear cells (PBMC) from healthy donors as exter-
nal effectors we demonstrated that daratumumab engages
ADCC in a panel of B-NHL cell lines (Table 1).
Daratumumab induced a significant dose-dependent cell
lysis reaching its maximum antitumor activity at 1 mg/mL
on MCL cell lines (mean ± standard deviation
[SD]=45±14%) (Figure 1A), at 0.1 mg/mL on FL cell lines
(mean ± SD=48±18%) (Figure 1B), and at 0.1 mg/mL on
DLBCL cell lines (mean ± SD=49±11%) (Figure 1C). The
degree of ADCC induction did not correlate with the
number of CD38 molecules per NHL cell specific antibody
binding capacity (sABC) (r2=0.1988; Online Supplementary
Figure S1A and Table 1). A phagocytosis assay using mouse
macrophages as effector cells was set up to determine
daratumumab-mediated ADCP. Daratumumab induced
significant ADCP at 1 mg/mL in MCL cell lines (mean ±
SD=54±24; Figure 1D), FL cell lines (mean ± SD=64±26%;
Figure 1E) and in DLBCL cell lines (mean ± SD=39±18%;
Figure 1F). The degree of ADCP induction did not corre-
late with the number of CD38 sABC on NHL cell lines
(r2=0.2270; Online Supplementary Figure S1B and Table 1).
Interestingly, the daratumumab-opsonized cells that
were exposed to macrophages and not phagocytosed, suf-
fered a lost in CD38 surface expression, irrespective of the
degree of ADCP induction (Online Supplementary Figure
S2), in a process that may resemble trogocytosis as previ-
ously described in MM studies.31,32
We next evaluated the CDC activity and observed that,
similar to that reported for CLL cells,30 daratumumab
induced low to marginal cell death in the presence of nor-
mal human serum (NHS 10%) (Table 1). Very similar
results were obtained in these CDC experiments when
50% NHS was applied. The high expression of the com-
plement regulatory proteins (CRP) CD46, CD55 and
CD59, and an insufficient number of CD38 molecules per
cell on NHL cells may explain the low CDC activity (Table
1). 
Collectively, daratumumab effectively kills CD38+ NHL
cells through engagement of ADCC and ADCP but not
CDC, independently of the expression levels of CD38.
Daratumumab enters and distributes homogeneously
within a 3D lymphoma model
To model the compact aggregates of lymphoma cells
growing in the patients’ lymph nodes, 3D spheroids were
generated by the hanging drop method,33 using RL-GFP
cells previously reported as an useful tool for antibody
therapy studies.34 We first sought to determine the degree
to which daratumumab can penetrate these lymphoma
aggregates depending on dose (1 and 10 mg/mL mAb) and
time of exposure (4, 24 and 48 hours). First, we measured
the percentage of mAb diffusion in the spheroid, repre-
senting the total amount of the mAb in the spheroid. The
3D reconstruction images obtained by SPIM (Figure 2A)
revealed a maximum diffusion of daratumumab at 1
mg/mL after 48 hours of treatment (Figure 2B). Next, max-
imum depth of daratumumab in the spheroids was deter-
mined under the same conditions and represented as per-
centage of mAb penetration in the spheroid. As observed
for the diffusion, a maximum penetration of daratumum-
ab at 1 µg/mL after 48 hours of treatment was achieved
A. Vidal-Crespo et al.
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Table 1. B-cell non-Hodgkin’s lymphoma cell lines characterization and daratumumab activity.
Cell line     NHL  subtype1         CD38 sABC2    %CD381   MFIR CD383   %CD201   MFIR CD203    %CD461   %CD551     %CD591      %ADCC4   %ADCP4     %CDC4
Jeko                      MCL                     16253                84                  22                  100                  46                    92              98                61               58               41                 7
REC-1                   MCL                    106234              100                155                 100                  77                    99              99                88               60               46                18
HBL2                    MCL                     25317               100                 92                  100                  99                    98              96                98               28               21                 0
Mino                     MCL                    127458              100                 51                  100                  42                    97             100               96               32               35                 0
UPN1                    MCL                     54089                99                  97                   97                    8                     98              99                63               36               73                 0
Z138                      MCL                    186239              100                120                 100                  28                   100             75                69               53               89                 0
DOHH2                  FL                       22369                87                  20                   99                   31                   100             76                98               25               38                 0
SC-1                        FL                       71726               100                 40                   32                    4                     95              96                83               41               81                 1
RL                           FL                      132684               96                  76                   93                   49                   100             94                97               52               45                 6
WSU-FSCCL         FL                       89707                97                 354                   8                     2                     82              81                94               67               92                 7
Toledo               DLBCL                  123539               99                 186                  89                   13                    94              99                97               34               50                14
WSU-DLCL2     DLBCL                   14926                94                  46                   99                  137                   95              95                98               45               15                 1
SU-DHL-6         DLBCL                  174033               92                 383                  98                  172                   97              44                31               64               56                 5
SU-DHL-4         DLBCL                   96623                96                 108                 100                  45                    93              45                95               61               34                 8
Daudi                     BL                      415667              100                276                  99                   30                    88              17                 9                63               79                96
1Percentage of positive cells for CD38, CD20, CD46, CD55 and CD59 determined by flow cytometry, referred to isotype control; 2sABC: number of surface antibodies bound per
cell evaluated by QuantiBRITETM CD38-PE; 3MFIR:  mean fluorescence ratio referred to isotype control; 4Percentage of antibody-dependent cellular cytotoxicity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP) induction at 1 mg/mL daratumumab. Percentage of CDC induction at 10 mg/mL daratumumab. MCL: mantle cell lymphoma,
FL: follicular lymphoma; DLBCL: diffuse large B-cell lymphoma; NHL: non-Hodgkin lymphoma; BL: Burkitt lymphoma. 
(Figure 2C). Moreover, a significant dose-dependent
reduction of the spheroid volume was observed after dara-
tumumab treatment compared to isotype control (mean ±
SD=15±6%, 20±7%, respectively at 1 and 10 mg/mL)
(Figure 2D) showing a direct effect of daratumumab on
tumor growth in 3D. This observation was validated in
additional lymphoma cell lines. Daratumumab moderate-
ly but significantly (P<0.0001) reduced the spheroid vol-
ume in all the cell lines analyzed, albeit in a different
degree (Online Supplementary Figure S3A-B), that was
accompanied in most of cases by a concomitant decrease
in the cell number. However, this observation did not
apply to HBL-2 and WSU-DLCL2 cell lines, where daratu-
mumab may just generate a tighter spheroid (Online
Supplementary Figure S3C).
These data demonstrate that daratumumab efficiently
penetrates a lymphoma 3D structure and moderately
reduces the growth of spheroids in the absence of external
effectors.
Daratumumab prevents tumor outgrowth in MCL and
FL xenografts
As a first test of daratumumab activity in vivo in NHL
models, we inoculated SCID mice sc with two cell lines
that we had previously set up: RL cells to model tFL,35 and
REC-1 cells to model MCL.36 SCID mice have active natu-
ral killer (NK) cells and macrophages that can act as effec-
tor cells to engage daratumumab activity, as we have
shown using in vitromodels. Mice were treated with dara-
tumumab or an isotype control (20 mg/kg) starting on the
day of tumor injection. Subsequently, animals received
antibody injections every other week (10 mg/kg) for a
total of three doses and were sacrificed at day 30 (REC-1)
(Figure 3A) or day 34 (RL) (Figure 3B). Daratumumab pre-
vented tumor formation in all mice injected with REC-1,
and in 5 of 6 mice injected with RL cells. In this latter
model, a 20 mm3 RL tumor was found in one daratumum-
ab-treated mouse at the endpoint (day 34). As the RL cells
inoculated expressed the luciferase gene, bioluminescence
analysis at different time points further supported these
results (Figure 3B). All animals receiving isotype control
antibody formed tumors of at least 100 mm3 within a
mean of 18 days (REC-1) and 21 days (RL) and were bigger
than 1,000 mm3 at the end of the experiment.
Daratumumab prolongs OS and reduces tumor 
infiltration in systemic xenograft models of MCL and FL 
Next, we generated a model for blastic MCL by inocu-
lating Z-138 cells intravenously into SCID mice, and one
week later mice were treated weekly with either daratu-
mumab (D), rituximab (R) or isotype (I) control
(20/10/10/10 mg/kg). Seven of ten isotype-treated mice
had to be sacrificed between days 57 - 89 due to systemic
signs of disease (Figure 4). Daratumumab significantly
improved OS (I vs. D: ***P<0.001), with 90% of the mice
treated with daratumumab surviving for over 107 days,
(Figure 4A) compared to just 10 % alive in the controls. OS
for the daratumumab group was slightly superior but did
not reach statistical significance (D vs. R: ns, P=0.2907),
compared to that observed in the rituximab-treated mice
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Figure 1. Daratumumab induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in the presence of external effectors in
non-Hodgkin lymphoma. (A) Mantle cell lymphoma (MCL), (B) follicular lymphoma (FL), and (C) diffuse large B-cell lymphoma (DLBCL) cell lines were treated with
increasing daratumumab doses (0.0001-1 mg/mL) in the presence of peripheral blood mononuclear cell (PBMC) from healthy donors at a E:T ratio of 50:1 for four
hours. Viability was then evaluated by calcein release assay. The Burkitt lymphoma (BL) cell line, Daudi, was included as positive control. (D) MCL, (E) FL, and (F)
DLBCL cell lines were labeled with calcein and incubated for 4 hours with the mΦ at an E:T ratio of 1:1 in the presence of a fixed daratumumab concentration of 1
mg/mL, followed by flow cytometry analysis in triplicates. Antibody-dependent cellular phagocytosis (ADCP) was calculated as the percentage of CD19+ calcein+F4/80-
cells after daratumumab treatment referred to isotype-treated cells. Daudi cells were included as positive control. ADCC: antibody-dependent cellular cytotoxicity
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(I vs. R: **P<0.01), where 70% of the mice were alive at
day 107 (Figure 4). Mean survival was 73 days for the con-
trol group, 97 for rituximab and 103 for daratumumab
groups. On autopsy, the disease had spread to the brain,
BM, spleen and lungs (Online Supplementary Figure S4A).
Daratumumab treatment reduced the disease burden in
the brain, BM, and spleen by 93%, 63%, and 48%, respec-
tively (Online Supplementary Figure S4B). Rituximab-treat-
ed mice showed a similar reduction in tumor load to that
achieved by daratumumab in the brain (73%) and BM
(69%) compared to that observed with the isotype con-
trol, while no effect was observed in spleen infiltration.
Finally, daratumumab did not diminish lung infiltration,
while a moderate reduction was seen in rituximab-treated
mice (18%) compared to isotype control mice (Online
Supplementary Figure S4B), suggesting an organ-dependent
differential immunotherapeutic response.
In the FL systemic model, CD20low WSU-FSCCL cells
(Table 1) were intravenously inoculated in SCID mice and
one week later mice were treated weekly with daratu-
mumab, rituximab or isotype control (20/10/10/10
mg/kg). All control-treated and rituximab-treated mice
rapidly succumbed to the disease and died or had to be
euthanized due to severe disease signs by day 40 (control
group) and day 62 (rituximab group), respectively (Figure
4). In contrast, in the daratumumab-treated group, OS was
significantly prolonged (I vs. D: ***P<0.001; I vs. R:
**P<0.01; D vs. R *P< 0.05). Mean survival was 35 days for
the control group, 41 for rituximab and 60 for daratumum-
ab. By the end of the experiment (day 90), 30% of mice
treated with daratumumab were cured (Figure 4). On
autopsy, WSU-FSCCL cells showed systemic dissemina-
tion of disease in the brain, BM and spleen (identified as
huCD45+/CD19+CD10+; Online Supplementary Figure S4C).
Daratumumab robustly decreased dissemination to the
brain (90%, P< 0.01) compared to the control group, while
rituximab was not effective (Online Supplementary Figure
S4D). Homing of WSU-FSCCL cells to the spleen and BM
was less prominent. There were no significant differences
in the reduction of dissemination to the spleen and BM by
daratumumab compared to the rituximab-treated group
(Online Supplementary Figure S4C).
Altogether, these data confirm that daratumumab
shows comparable to superior activity with respect to rit-
uximab in systemic models of MCL and FL. 
Daratumumab synergizes with R-CHOP to reduce tumor
burden in pre-clinical models of MCL and FL
The synergy between daratumumab and rituximab
and/or chemotherapy regimens was evaluated in MCL
(REC-1) and tFL (RL) xenograft heterotopic models. SCID
mice were inoculated subcutaneously with NHL cells and
when tumors became palpable, mice were randomly
assigned into the following groups: i) Isotype ii) daratu-
mumab iii) CHOP iv) D-CHOP v) R-CHOP and vi) R-D-
CHOP. Tumor volume was assessed twice a week and
tumor weights at sacrifice. In the MCL model (Figure 5A),
daratumumab induced significant anti-tumor activity
A. Vidal-Crespo et al.
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Figure 2. Daratumumab effect in a three-dimensional model of follicular lymphoma. Three-dimesional (3D) spheroids of RL-GFP cells were obtained after three days
of culture in hanging drop plates or 96-well ultra-low attachment plates, and then treated with 10 mg/mL of Isotype control (IgG1), or 1 or 10 mg/mL of daratumumab
at different times. (A) 3D reconstruction images produced by SPIM; fluorescence was measured at a lex of 488nm (GFP) and 561nm (monoclonal antibody [mAb]
labeling). (B) Percentage of mAb diffusion, representing quantity of the mAb in the spheroid. (C) Percentage of mAb penetration, representing maximum depth of the
mAb in the spheroid. (D) Spheroid volume (mm3) time course (n=number of spheroids per treatment). Statistical differences between groups were assessed by
unpaired t-test (**P<0.01; ***P<0.001).
compared to the isotype control (42%, P< 0.01). CHOP
alone marginally reduced tumor growth (P=0.182) and no
difference was observed between daratumumab and D-
CHOP groups (P=0.451). Importantly, adding rituximab
to D-CHOP treatment (R-D-CHOP) induced a significant
reduction in tumor volume compared to the isotype con-
trol (86%, P<0.001) and also compared to R-CHOP (73%,
P<0.001) and D-CHOP (51%, P< 0.05) alone. Similarly, in
the tFL model (Figure 5C-D), daratumumab treatment
inhibited tumor growth compared to isotype control
(36%, P<0.001). On the other hand, the combination D-
CHOP inhibited tumor growth significantly better than
daratumumab as a single agent (57%, P<0.001), resem-
bling that achieved by R-CHOP (67%, P<0.001). In addi-
tion, the combination regimen of R-D-CHOP had a
remarkable effect in impeding tumor growth (84% inhi-
bition, P<0.001), which was superior than that achieved
by each combination regimen separately (P<0.001). The
results of the RL-luc model were further validated by bio-
luminescence and quantification of the signal captured at
the endpoint (Online Supplementary Figure S5A-B).
Moreover, tissue sections of selected mice of each group
were analyzed by immunohistochemistry for the prolifer-
ation marker pH3 and the angiogenesis marker CD31,
further confirming these results (Online Supplementary
Figure S5C).
In conclusion, these data demonstrate the value of the
combination R-D-CHOP as a new therapeutic strategy in
MCL and tFL superior to the standard-of-care (R-CHOP).
Daratumumab induces tumor growth inhibition and
prolongs survival in a patient-derived DLBCL xenograft
model in combination with R-CHOP
To further evaluate the activity of daratumumab alone
or in combination with the standard-of-care therapy we
used a clinically more relevant patient-derived DLBCL
xenograft model (ST1361) with detectable CD38 expres-
sion by immunohistochemistry (Online Supplementary
Figure S6). Identical to the MCL and tFL models, all indi-
vidual treatments were capable of reducing tumor volume
over time (P<0.001, Figure 6A); however, daratumumab
alone was strikingly efficient with an anti-tumor activity
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Figure 3. Daratumumab efficacy in pre-emptive models of mantle cell lymphoma and transfomed follicular lymphoma. 10x106 REC-1 cells (A) or RL-luc cells (B)
were mixed with matrigel (1:1) and subcutaneously injected in SCID mice (n=6 per group). Animals received one dose every other week (10 mg/kg of isotype control
[IgG1] or dartumumab) starting the day of cell inoculation. Tumor growth curves over time clearly show total regression was achieved in both models. As RL cell line
expressed the luciferase gene, sequential bioluminescence images were captured at different time points (B). Statistical differences between groups were assessed
by unpaired t-test (***P<0.001). MCL: mantle cell lymphoma; tFL: transfomed follicular lymphoma.
Figure 4. Daratumumab monotherapy in a systemic model of mantle cell lymphoma and follicular lymphoma compared to rituximab. 10x106 Z-138 mantle celle
lymphoma (MCL) and WSU-FSCCL follicular lymphoma (FL) cells were intravenously injected in SCID mice (n=10 per group). Treatment (isotype control [IgG1]/ dara-
tumumab/ rituximab) started one week after inoculation and went on weekly for four weeks (20/10/10/10 mg/kg), as indicated by the red arrows. Mice were mon-
itored twice weekly for any sign of disease and were euthanized when body weight decreased 15-20%. Survival curves are represented. Statistical differences
between groups were assessed by log-rank test. Z-138: Overall significance***P<0.001; Isotype; control vs. daratumumab ***P<0.01; daratumumab vs. rituximab
not signficant (ns) P=0.2907. WSU-FSCCL: Overall significance ***P<0.001; isotype control vs. daratumumab ***P≤0.001; daratumumab vs rituximab  *P=0.045. 
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comparable to R-CHOP (P<0.001, Figure 6A).
Furthermore, the addition of daratumumab to either
CHOP or R-CHOP led to full tumor regression (P<0.001,
Figure 6A). Importantly, tumor volume negatively corre-
lated very well with the OS of xenograft-bearing mice,
regardless the treatment group (Figure 6B). Thus, mice
treated with either daratumumab alone or R-CHOP dis-
played identical OS and, in line with the full tumor regres-
sion achieved, daratumumab combined with either
CHOP or R-CHOP resulted in 100% survival at the end of
the experiment (P<0.05 after Bonferroni multiplicity cor-
rection, Figure 6A).  Remarkably, full tumor regression and
100% survival at day 60 were observed even when dara-
tumumab treatment was ceased as early as 14 days (total
of three doses) after tumor cell inoculation. Collectively,
these results indicate that tumor cells were completely
eliminated within a short time and that no tumor escape
occurred in this DLBCL patient-derived model. 
Discussion
In this study we have demonstrated that daratumumab
engages Fc-mediated cell killing of NHL cells by ADCC
and ADCP. Variation in the extent of ADCC and ADCP
could not be explained by the differences in CD38 expres-
sion levels. Similar observations were also reported for
daratumumab-induced ADCC and ADCP in CLL cells.30
The capacity of daratumumab to induce ADCC and
phagocytosis may to some extent be related to other fac-
tors, such as the expression of different types of FcgR,
KIRs and Natural Cytotoxic Receptors (NCR) on NK
cells.37 Moreover, the expression of the so-called ‘don’t eat
me’ signals, such as CD47, on tumor cells plays an impor-
tant role in regulating phagocytosis. In fact, CD47 expres-
sion has been found to be increased on MCL, FL and
DLBCL cells compared to normal cells, conferring a worse
clinical prognosis.38 Moreover, in agreement with previous
results in MM,32 the daratumumab-opsonized cells that
were exposed to macrophages and not phagocytosed, suf-
fered a loss in CD38 surface expression. This event may
reduce the ability of daratumumab to kill lymphoma cells
via CDC and ADCC, compromising the therapeutic effi-
cacy of daratumumab. However, MM studies demonstrat-
ed that this phenomenon occurs early in the treatment
irrespective of their clinical responses.32 Therefore, CD38
reduction via trogocytosis should not necessarily be con-
sidered as an escape mechanism from daratumumab treat-
ment. On the contrary, trogocytosis may be beneficial and
represent a novel mechanism of action of daratumumab,
as there is also a transfer of tumor cell membrane frag-
ments containing important signaling molecules such as
CD56 CD49d and CD138 in this process. The decreased
expression of these adhesion molecules in tumor cells may
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Figure 5. Daratumumab combined with R-CHOP in mantle cell lymphoma and transformed follicular lymphoma. 10x106 REC-1 (A-B) and RL-luc (C-D) cells were
mixed with matrigel (1:1) and subcutaneously injected in SCID mice (REC-1: n=5-7 per group; RL: n=7-10 per group). Treatment as monotherapy (isotype control
[IgG1]/ daratumumab/ rituximab/ CHOP) or the combination regimen DARA ± RITUX ± CHOP started one week after inoculation and went on weekly for three weeks
for the monoclonal antbodies (mAb) (20/10/10 mg/kg) in the REC model, and four weeks (20/10/10/10 mg/kg) for the RL model.  CHOP was given as an initial
unique dose the first day of treatment in both models. Tumor growth curves over time are represented for each cohort (A and C). Tumor weight for each treatment
was averaged and represented at endpoint for REC-1 (B) and RL models (D). Statistical differences between groups were assessed by unpaired t-test (**P<0.01;
***P<0.001).
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compromise their interaction with the tumor microenvi-
ronment as we reported in a previous work.30
Daratumumab did not induce CDC in FL, or DLBCL or
MCL cell lines. Flow cytometry analysis demonstrated
that MCL and FL cells show medium to high expression of
CD38 while DLBCL cells tend to express higher levels of
CD38. However, the number of molecules per cell in these
NHL cell lines was lower than that found on the CDC-
sensitive Daudi Burkitt lymphoma cell line, suggesting a
threshold for CD38-targeted CDC lysis. In addition, this
low induction of CDC was also associated with high
expression of the CRP CD55 and CD59 that were lower
in Daudi cells. These observations are in line with our pre-
vious data obtained for CLL cell lines and primary cells.30
Overall, the baseline expression of CD38/CD55/CD59
appears to be associated with the response to daratumum-
ab-induced CDC in vitro in FL, DLBCL and MCL cells.
These results mirrored those obtain with the anti-CD20
rituximab in CLL cells.39
We have shown for the first time that daratumumab, at
clinically achievable doses, effectively penetrates a lym-
phoma organoid in vitro model. A moderate but significant
reduction of the sphere volume was observed with daratu-
mumab in 3D lymphoma models, even though no signifi-
cant effect was observed in a 2D model (data not shown).
These results agree with daratumumab efficacy against
subcutaneous tumors in vivo (Figure 5 and Figure 6).
In vivo results support the ability of daratumumab to pre-
vent the outgrowth of MCL and FL cells, when adminis-
tered in a prophylactic setting, prior to tumor develop-
ment. These results open a window of opportunity for
daratumumab as an alternative to rituximab maintenance
therapy in these models, in the context of a complete
response after the induction therapy.40,41 Moreover, we
have demonstrated that daratumumab shows single agent
activity both in systemic and subcutaneous models of
NHL, when administered after disease onset. More impor-
tantly, the data from the FL model using WSU-FSCCL cells
point to a possible role for daratumumab as a therapeutic
alternative to rituximab in NHL with reduced CD20
expression. Previous studies have shown a substantial and
rapid reduction of CD20 in lymphoma patients treated
with rituximab, which has been linked to the development
of acquired resistance.42,43 Thus, daratumumab treatment
may be considered in these scenarios where anti-CD20
resistance has developed due to antigen shaving.44 In addi-
tion, our results indicate that daratumumab significantly
improves long-term survival when used as a single agent,
indicating that it may be also an alternative to rituximab in
NHL CD20high, evidenced by the comparable activity of
both antibodies in the blastic MCL model using Z-138
cells.  We have also observed a remarkable effect of dara-
tumumab in the tumor cell dissemination to the brain in FL
and MCL systemic models. This may be related to the
capacity of daratumumab to cross the hemato-encephalic
barrier. In fact, daratumumab has shown efficacy in CNS
plasmocytoma45 and extramedullary myeloma.46 
Finally, we have examined the combination of daratu-
mumab with the standard-of-care therapy R-CHOP. Our
data suggest that daratumumab significantly potentiates
R-CHOP activity, inducing higher rates of tumor regres-
sion in MCL and FL. Moreover, we analyzed the efficacy
of daratumumab in a DLBCL patient derived mouse
xenograft, generated from a transformed FL, and usually
less responsive to chemotherapy, as shown in our results
where indeed the CHOP regimen displayed limited activ-
ity. In this model, daratumumab in combination only with
CHOP, in the absence of rituximab leads to a complete
abrogation of tumor growth. This strong synergy may be
explained by the induction of stress-related cytokines by
chemotherapeutic agents that can effectively target cancer
cells for removal by the innate immune system through
macrophage infiltration and phagocytic activity,47 poten-
tially augmenting the described ability of daratumumab to
engage ADCP.26
In the phase II clinical trial CARINA, LYM2001 in R/R
NHL, daratumumab monotherapy did not yield the
expected results in heavily pretreated FL and DLBCL
patients, while no results could be concluded in MCL
because of insufficient patient recruitment. However, we
have identified certain NHL scenarios were daratumumab
shows comparable antitumor activity as rituximab (blastic
Daratumumab in B-NHL
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Figure 6. Daratumumab combined with R-CHOP in a patient-derived diffuse large B-cell lymphoma xenograft model. Fragments from a patient-derived diffuse large
B-cell lymphoma (DLBCL) were injected subcutaneously into SCID mice (n=8-10) and staged to approximately 150-250 mm3 mean tumor volume to measure (A)
tumor growth and (B) overall survival (OS).  20 mg/kg daratumumab was administered weekly alone or in combination with CHOP (20 mg/kg cyclophosphamide,
1.25 mg/kg doxorubicin, 0.2 mg/kg vincristine, and 0.15 mg/kg prednisone) or R-CHOP (10 mg/kg rituximab+ CHOP) for a total of three weeks.
  A   B
MCL) and other where exhibits superiority (transformed
CD20dim FL). Moreover, daratumumab potentiates the
antitumor activity of CHOP and R-CHOP in all three
models. 
In addition, as demonstrated in MM, it is likely that
daratumumab may modulate the activity and frequency
of CD38 expressing immune suppressive cell populations
present in NHL, an effect not exerted by rituximab, and
therefore may offer a superior overall antitumor effect.29
These may be of special relevance in FL and DLBCL where
infiltration of diverse T and myeloid subpopulations is
specially prominent.48 The immune-compromised mouse
models used in this study preclude the analysis of this
immune-modulating activity of daratumumab. 
In conclusion, our findings warrant further clinical
development of daratumumab in NHL providing a strong
rationale for examining its clinical efficacy in different sce-
narios, including maintenance therapy after induction
therapy, cases with anti-CD20 resistance, FL histologic
transformation, and as frontline in combination with the
standard of care (CHOP/ R-CHOP). 
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